Posted: August 5, 2021 at 1:55 am
MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the first patient has been dosed in its ‘CUPID’ first-in-human Phase I study of the Company’s next generation prostate cancer therapy candidate TLX592 in patients with advanced prostate cancer.
Continued here:
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Posted: August 5, 2021 at 1:55 am
SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced they have entered into a research collaboration in 2021. As part of the partnership, Imugene and Celularity will initially collaborate to develop the combination of Imugene’s CD19 oncolytic virus technology and Celularity’s CD19 targeting allogeneic chimeric antigen receptor (CAR) T cellular therapy, CyCART-19, for the treatment of solid tumors. CyCART-19 is a placental-derived T-cell investigational therapy engineered with a CAR that is cryopreserved and will be available off-the-shelf.
The rest is here:
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy...
Posted: August 5, 2021 at 1:55 am
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-
Read more:
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
Posted: August 5, 2021 at 1:55 am
Geneva, Switzerland, August 5, 2021 - Ad Hoc Announcement Pursuant to Art. 53 LR
Original post:
Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update
Posted: August 5, 2021 at 1:55 am
Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough Designation status by the Food and Drug Administration (FDA).
Read the rest here:
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
Posted: August 5, 2021 at 1:55 am
BASEL, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in Tourette Syndrome.
Read the original:
Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome
Posted: August 5, 2021 at 1:55 am
Just about everyone would agree that a child born in Australia should have the same opportunities and rights as any other Australian child. Race, disability, or religious belief should not be a barrier to what they can do or what they can achieve or where they can go.
These are human rights. They are built into various declarations that form cornerstones of liberal democracies around the world.
But what about human rights regarding their medical status?
The Prime Minister, Scott Morrison, has signalled that states may be allowed to stop people from travelling based on whether or not they have been vaccinated. Surely we need to talk about the ethics of this.
Vaccines are unlike other medicines because they dont seek to cure illness or return us to our normal function. They provide upgrades to our natural characteristics namely immunity.
There is a word to describe changing the characteristics of humans like this it is transhumanism.
If you think this sounds like science fiction you would be right. The 1997 dystopian movieGattaca is the common pop culture reference for discussions around the ethics of transhumanism. In this film a genetic registry database is used to classify people who are created with eugenics as valids while people who are conceived naturally and more susceptible to diseases are known as invalids.
There are already some intriguing developments in transhumanism. Recently, there has been progress on developing mind-controlled prosthetics that may allow prosthetic limbs to convey sensation to amputees. Its a small step from using this technology for restoring bodily function to upgrading it. Nootropic or performance-enhancing drugs, which improve cognitive or physical abilities, could also create a form of transhumanism.
An important distinction is that these actions do not confer special rights that are denied to others, but we should have no problem with informed individuals choosing to change themselves.
But the pandemic is a game-changer. It means that government policy on this issue could impact on hundreds of millions of people. The pandemic led to a massive effort around the world to develop vaccines, and the emergence of new technologies such as mRNA vaccines have the potential to revolutionise medical care.
So the future has arrived, but have the ethics been fully considered? Medical technology has the capability of creating different categories of humans and, if we are not careful, a new tier of second class citizens - the invalids.
Should the state discriminate against a person who is unvaccinated? Or should they protect them from discrimination?
What about those left behind? Allowing states to discriminate against people who choose not to be vaccinated is a form of medical apartheid. It has the potential to be a major problem for unvaccinated people from remote areas or third world countries which would be like discriminating against people for being simply human and poor.
It could also be a problem for others who may have religious or medical reasons not to have a jab, or children who remain unvaccinated through no choice of their own.
Before we start locking people out of states and denying their right to freedom of movement, this is a very serious ethical issue that should be discussed and considered from a human rights perspective.
Unfortunately, the form is not good, because we have seen many human rights issues tossed aside during the pandemic with little or no thought.
The Victorian Ombudsmans office is the only independent body to have investigated human rights issues in detail in relation to the pandemic. Following an investigation into the lockdown of public housing towers in Melbourne last year, Ombudsman Deborah Glass found the actions of the government breached the Victorian Human Rights Charter.
Despite her damning report, it seems doubtful the Victorian Government learnt anything at all, because they still refuse to apologise.
This example of a disproportionate response is just the tip of the iceberg.
Forget about circuit breaker lockdowns, we need to break the circuit of government over-reach. We need to take at least a little time to reassess the implications for human rights.
Are we marching blindly into a world where discrimination against people for simply being human becomes acceptable and commonplace? Im sure that some will argue that this is an emergency and the normal rules shouldnt apply. But if we abandon our principles for this, then what are they worth?
We can start by respecting peoples liberty and their medical choices. We need to stop demonising people who, for whatever reason, would rather not have the needle or are unable to be vaccinated.
David Limbrick is the Liberal Democrats MLC for Victorias South East Metropolitan region.
Excerpt from:
Why haven't we heard more from the human rights bureaucracy about Covid and our liberties? - The Spectator Australia
Posted: August 5, 2021 at 1:55 am
Filming is underway in Europe on David Cronenbergs Crimes Of The Future, starring Viggo Mortensen, La Seydoux, Kristen Stewart and Scott Speedman.
Joining the cast are Tanaya Beatty (Yellowstone), Nadia Litz (Big Muddy), Yorgos Karamichos (The Durrells), and Yorgos Pirpassopoulos (Beckett). Also previously announced were Welket Bungu (Berlin Alexanderplatz), Don McKellar (Blindness), and Lihi Kornowski (Losing Alice).
The film shoots in Athens, Greece until September 2021.
The film takes a deep dive into the not-so-distant future where humankind is learning to adapt to its synthetic surroundings. The evolution moves humans beyond their natural state and into a metamorphosis, altering their biological makeup. While some embrace the limitless potential of transhumanism, others attempt to police it. Either way, Accelerated Evolution Syndrome, is spreading fast.
As we begin filming Crimes Of The Future, just two days into this new adventure with David Cronenberg, it feels like weve entered a story he collaborated on with Samuel Beckett and William Burroughs, if that were possible, said Mortensen. We are being pulled into a world that is not quite like this or any other, and yet is one that feels strangely familiar, immediate and quite credible. I cant wait to see where we end up.
Produced by Robert Lantos, the film reunites Cronenberg with three-time Oscar nominee Mortensen in their fourth collaboration. The movie marks Cronenbergs first original screenplay since eXistenZ in 1999. The film is also the fourth collaboration between Lantos and Cronenberg.
Panos Papahadzis is producer for Athens-based Argonauts Productions and Steve Solomos is co-producer. Executive producers include Joe Iacono, Thorsten Schumacher, Peter Touche, Christelle Conan, Aida Tannyan, Victor Loewy, and Victor Hadida. Bonnie Do and Laura Lanktree are associate producers.
Production designer is Carol Spier (Crash) and composer is Howard Shore (The Lord Of The Rings Trilogy). Douglas Koch (Funny Boy) is cinematographer, with Mayou Trikerioti (Pari) as costume designer, Dimitris Katsikis (Fugitive Pieces) as art director, and Stefanos Efthymiou is sound recordist.
Pic will be distributed worldwide by distributors including Neon (USA), MK2|Mile End (Canada), Metropolitan (France), Weltkino (Germany, Austria and Switzerland), The Searchers (Benelux), Argonauts Productions (Greece), Front Row (Middle East), Capella (CIS/ the Baltic States), and Moviecloud (Taiwan). Rocket Science is handling international sales.
The Canada-Greece co-production is produced in association with Ingenious Media, Coficine, Telefilm Canada, Bell Media, CBC, and the Harold Greenberg Fund, with the support of EKOME and the GFC.
Posted: August 5, 2021 at 1:52 am
Abstract: Global Stem Cell Banking Market to Reach US$11. 3 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for Stem Cell Banking estimated at US$7.
New York, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Banking Industry" - https://www.reportlinker.com/p05799719/?utm_source=GNW 1 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 6.8% over the analysis period 2020-2027.Placental and Cord Blood Stem Cells, one of the segments analyzed in the report, is projected to grow at a 7.4% CAGR to reach US$7.3 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adipose Tissue-Derived Stem Cells (ADSCS) segment is readjusted to a revised 6.3% CAGR for the next 7-year period. This segment currently accounts for a 6.6% share of the global Stem Cell Banking market.
The U.S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 6.4% CAGR for the Period of 2020-2027
The Stem Cell Banking market in the U.S. is estimated at US$2.1 Billion in the year 2020. The country currently accounts for a 29.55% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$2 Billion in the year 2027 trailing a CAGR of 6.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR while Rest of European market (as defined in the study) will reach US$2 Billion by the year 2027.
Bone Marrow-Derived Stem Cells (BMSCS) Segment Corners a 10.3% Share in 2020
In the global Bone Marrow-Derived Stem Cells (BMSCS) segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$592.8 Million in the year 2020 will reach a projected size of US$858.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.
Select Competitors (Total 78 Featured)
Story continues
Cord Blood Registry
CordLife Group Ltd.
Cryo-Cell International, Inc.
Cryo-Save AG
Global Cord Blood Corporation
LifeCell International Pvt., Ltd.
Smart Cells International Ltd.
StemCyte Inc.
ViaCord
Vita 34 AG
Read the full report: https://www.reportlinker.com/p05799719/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Stem Cells, Application Areas, and the Different Types - A Prelude Applications of Stem Cells Types of Stem Cells Cord Blood Umbilical Cord Tissue Bone Marrow Stem Cells Adipose-Derived Stem Cells (ADSCs) Number of Clinical Trials Using Adipose Stem Cells: 2007-2018 Number of Adipose Stem Cell Trials by Phase: 2007 to 2018 Human Embryo-Derived Stem Cells (HESCS) Global Stem Cell Banking Market Poised for a Rapid Growth Developed Regions Lead, Emerging Economies to Spearhead Future Growth List of Family Cord Blood Banks in the US Placental and Cord Blood Banks Dominate the Cord Blood Banking Market Global Number of Annual Newborns and Private Cord Blood Banks Global Select Leading Cord Blood Banks Based on Inventory A Peek into China?s Cord Blood Banking Industry Evolving Landscape of Cord Blood Banking Industry Placental Stem Cells and Potential Clinical Applications EXHIBIT 1: Global Cord Blood Banking Market Share Breakdown (%) by Bank Type: 2019 EXHIBIT 2: US Cord Blood Banking Market by Bank Type (in %) for 2019 Changing Business Models for Stem Cell Banking
2. FOCUS ON SELECT PLAYERS Cord Blood Registry (CBR) Systems, Inc. (USA) Cordlife Group Limited (Singapore) Cryo Stemcell Private Limited (India) Cryo-Cell International, Inc. (USA) Cryoviva Biotech Private Limited (India) Global Cord Blood Corporation (China) LifeCell International Pvt. Ltd (India) Smart Cells International Ltd. (UK) StemCyte (USA) Takara Bio Europe AB (Europe) ViaCord (US) Vita34 AG (Germany)
3. MARKET TRENDS & DRIVERS Increasing Investments in Stem Cell-Based Research Widen Prospects for Stem Cell Banking Market EXHIBIT 3: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017 Stem Cell Research Policies Impact Funding Volumes Adult Stem Cell Research Gains Traction, Accelerating Research Funding Adult Stem Cells Vs. Embryonic Stem Cells: A Comparison Embryonic Stem Cell Research Bogged Down by Ethical Issues & Technical Hurdles Induced Pluripotent Stem Cell (iPSC) Research: The Latest Vertical Sustained Emphasis on Mesenchymal Stem Cell Research Emergence of Advanced Technologies for Stem Cell Preservation, Storage and Processing Augurs Well for Market Growth Growing Incidence of Major Diseases to Boost the Demand for Stem Cells, Driving Stem Cell Banking EXHIBIT 4: Worldwide Incidence of Cancer (2012, 2018 & 2040): Number of New Cases Diagnosed Table 8: World Cancer Incidence by Cancer Type (2018): Number of New Cancer Cases Reported (in Thousands) for Breast, Cervix uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach and Others
Table 9: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Table 10: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) Ageing Demographics to Drive Demand for Stem Cell Banking Global Aging Population Statistics - Opportunity Indicators Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2017 & 2050)
Table 4: Global Aging Population (2017 & 2050): Population of 60+ Individuals in ?000s and as a Percentage of Total Population
Table 5: Life Expectancy for Select Countries in Number of Years: 2018 Bone Marrow Stem Cells Market on a Rapid Growth Path, Spurring the Need for Stem Cell Banking Development of Regenerative Medicine Accelerates Demand for Mesenchymal Stem Cell Banking Table 2: Global Regenerative Medicines Market by Category (2019): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering Rise in Volume of Orthopedic Procedures Boosts Prospects for Stem Cell Banking Table 1: Global Orthopedic Surgical Procedure Volume (2010-2020) (in Million) Increasing Demand for Stem Cell Based Bone Grafts: Promising Growth Ahead for Stem Cell Banking Rise in the Number of Hematopoietic Stem Cell Transplantation Procedures Propels Market Expansion Hematopoietic Stem Cell Storage Dental Mesenchymal Stem Cells: An Evolving Niche Therapeutic Potential of Dental Pulp Stem Cells (DPSCs) in Various Diseases High Operational Costs of Stem Cell Banking - A Key Market Restraint
4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World 7-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
Table 3: World Current & Future Analysis for Placental and Cord Blood Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 4: World 7-Year Perspective for Placental and Cord Blood Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 5: World Current & Future Analysis for Adipose Tissue-Derived Stem Cells (ADSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 6: World 7-Year Perspective for Adipose Tissue-Derived Stem Cells (ADSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 7: World Current & Future Analysis for Bone Marrow-Derived Stem Cells (BMSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 8: World 7-Year Perspective for Bone Marrow-Derived Stem Cells (BMSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 9: World Current & Future Analysis for Human Embryo-Derived Stem Cells (HESCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 10: World 7-Year Perspective for Human Embryo-Derived Stem Cells (HESCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 11: World Current & Future Analysis for Dental Pulp-Derived Stem Cells (DPSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 12: World 7-Year Perspective for Dental Pulp-Derived Stem Cells (DPSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 13: World Current & Future Analysis for Other Stem Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 14: World 7-Year Perspective for Other Stem Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 15: World Current & Future Analysis for Sample Preservation and Storage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 16: World 7-Year Perspective for Sample Preservation and Storage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 17: World Current & Future Analysis for Sample Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 18: World 7-Year Perspective for Sample Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 19: World Current & Future Analysis for Sample Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 20: World 7-Year Perspective for Sample Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 21: World Current & Future Analysis for Sample Collection and Transportation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 22: World 7-Year Perspective for Sample Collection and Transportation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 23: World Current & Future Analysis for Personalized Banking Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 24: World 7-Year Perspective for Personalized Banking Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 25: World Current & Future Analysis for Research Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 26: World 7-Year Perspective for Research Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 27: World Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 28: World 7-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES Table 29: USA Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 30: USA 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027
Table 31: USA Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 32: USA 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027
Table 33: USA Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 34: USA 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027
CANADA Table 35: Canada Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 36: Canada 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027
Table 37: Canada Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Canada 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027
Table 39: Canada Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 40: Canada 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027
JAPAN Table 41: Japan Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 42: Japan 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027
Table 43: Japan Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: Japan 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027
Table 45: Japan Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 46: Japan 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027
CHINA Table 47: China Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 48: China 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027
Table 49: China Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 50: China 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027
Table 51: China Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 52: China 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027
EUROPE Table 53: Europe Current & Future Analysis for Stem Cell Banking by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 54: Europe 7-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Table 55: Europe Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 56: Europe 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027
Table 57: Europe Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 58: Europe 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027
Table 59: Europe Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 60: Europe 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027
FRANCE Table 61: France Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 62: France 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027
Table 63: France Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 64: France 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027
Table 65: France Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 66: France 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027
GERMANY Table 67: Germany Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 68: Germany 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027
Table 69: Germany Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 70: Germany 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027
Table 71: Germany Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Continue reading here:
Global Stem Cell Banking Market to Reach US$11.3 Billion by the Year 2027 - Yahoo Finance
Posted: August 5, 2021 at 1:52 am
(Precision Vaccinations)
New York-based Regeneron Pharmaceuticals, Inc.announced that theU.S. Food and Drug Administration(FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV.
The FDA's EUAnow includes post-exposure prophylaxis in people at high risk for progression to severe COVID-19, who are not fully vaccinated or are not expected to mount an adequate response to vaccination, and have been exposed to a SARS-CoV-2 coronavirus infected individual, or who are at high risk of exposure to an infected individual because of infection occurring in the same institutional setting (such as in nursing homes or prisons).
Additionally, for those who require repeat dosing for ongoing exposure, REGEN-COV can also now be administered monthly.
This new indication in people aged 12 and older is in addition to the previously granted EUAto treatnon-hospitalized patients.
"Today's FDA authorization enables certain people at high risk ofdeveloping severe COVID-19 infectionto access REGEN-COV if they have beenexposedto the virus the first time an antibody treatment has been authorized for this purpose," statedGeorge D. Yancopoulos, M.D., Ph.D., President and CEOof Regeneron, in a press statement issued on July 30, 2021.
"With this authorization, the FDA specifically highlights the needs of immunocompromised people, including those taking immunosuppressive medicines, who may not mount an adequate response to (COVID-19) vaccination."
And "who are exposed to a person with COVID-19 or are in an institutional setting and are at high risk of exposure because of infection occurring in the same setting."
The "FDA decision to expand the use of REGEN-COV in post-exposure settings is a very helpful step, and we continue to work with the FDA as it undertakes its review of REGEN-COV in a broader group of people including in a pre-exposure prophylactic setting for people who are immunocompromised, and in patients hospitalized due to COVID-19."
Experts estimate that approximately 3% of theU.S.population may not respond fully to COVID-19 vaccination because of immunocompromising conditions or immunosuppressive medicines.
This group includespeople receiving chemotherapy, people with hematologic cancers such as chronic lymphocytic leukemia, people receiving stem cells or hemodialysis, people who have received organ transplants, and/or people taking certain medications that might blunt immune response (e.g., mycophenolate, rituximab, azathioprine, anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhibitors).
This new FDA EUAenables these groups to use REGEN-COV to prevent infection in post-exposure and certain institutional settings.
Under the EUA for post-exposure prophylaxis, REGEN-COV can be administered by subcutaneous injection or intravenous infusion.
For people who aren't expected to mount an adequate immune response to vaccination and have ongoing exposure to SARS-CoV-2 for more than four weeks, the initial 1,200 mg dose can be followed by subsequent repeat dosing of REGEN-COV 600 mg once every four weeks, for the duration of ongoing exposure.
Note:REGEN-COV is not a substitute for vaccination against COVID-19 and is not authorized for pre-exposure prophylaxis to prevent COVID-19. And the U.S. CDCdefines close contact as someone who has been withinsix feet of an infected person(laboratory-confirmed or aclinically compatible illness) for a cumulative total of 15 minutes or more over a 24-hour period.
Read the original:
COVID-19 Antibody Therapy Now Available For Treatment and Post-Exposure Prophylaxis - PrecisionVaccinations
